Clinuvel Pharmaceuticals (CUV) AGM 2024 summary

Opening remarks and agenda

• Meeting opened with acknowledgment of traditional land owners, confirmation of quorum, and compliance with convening requirements.

• Agenda included Chair's address, Managing Director's presentation, focus on vitiligo, Q&A sessions, and formal business with voting.

• Expressed gratitude to long-term supporters, Board of Directors, and staff for their commitment and contributions.

• Paid tribute to Professor Marcus Maurer, recognizing his impact on dermatology.

Financial performance review

• Achieved strongest financial year since listing, with robust commercial operations in Europe and North America.

• Earnings per share at AUD 0.715 (diluted AUD 0.698), return on equity 17.6%, and after-tax profit of AUD 35.6 million.

• Cash reserves reached A$183.9m, revenues A$95.3m, and earnings A$35.9m as of October 2024.

• Product portfolio expanded to 2 marketed products and 9 in the pipeline.

• Price-to-earnings ratio improved to 20 in October 2024, down from 67 in January 2023.

Board and executive committee updates

• Three new non-executive directors appointed, bringing expertise in finance, governance, M&A, and dermatology.

• CEO agreed to a one-year contract extension, with succession planning underway for a new CEO by June 2026.

• Recent recruitment included a new CFO, Director of Global Clinical Affairs, and Company Secretary.

• Board authorized the AGM release and reaffirmed commitment to transparency and investor relations.

• Farewell to a long-serving director after 17 years of service.